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The ability to investigate therapeutic interventions in animal models of neurodegenerative
diseases depends on extensive characterization of the model(s) being used. There
are numerous models that have been generated to study Alzheimer’s disease (AD)
and the underlying pathogenesis of the disease. While transgenic models have been
instrumental in understanding AD mechanisms and risk factors, they are limited in the
degree of characteristics displayed in comparison with AD in humans, and the full
spectrum of AD effects has yet to be recapitulated in a single mouse model. The Model
Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (MODEL-
AD) consortium was assembled by the National Institute on Aging (NIA) to develop more
robust animal models of AD with increased relevance to human disease, standardize
the characterization of AD mouse models, improve preclinical testing in animals, and
establish clinically relevant AD biomarkers, among other aims toward enhancing the
translational value of AD models in clinical drug design and treatment development.
Here we have conducted a detailed characterization of the 5XFAD mouse, including
transcriptomics, electroencephalogram, in vivo imaging, biochemical characterization,
and behavioral assessments. The data from this study is publicly available through the
AD Knowledge Portal.
Keywords: Alzheimer’s disease, phenotyping, animal model, early-onset AD, MODEL-AD
INTRODUCTION
Alzheimer’s disease (AD) is the leading cause of dementia, and there are currently no effective
intervention strategies to prevent, slow, or reverse the disease process (Citron, 2010; Karch et al.,
2014). The number of people affected by AD in the US is expected to rise to 13.8 million by
2050, and the worldwide financial burden of the disease is projected to reach $9.12 trillion in
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the same time-frame (Jia et al., 2018), highlighting the critical
need for the development of novel therapeutics (Hebert et al.,
2013). The primary characteristics of AD are extracellular
parenchymal β-amyloid (Aβ) plaque formation and intracellular
accumulation of hyperphosphorylated tau in neurofibrillary
tangles (NFTs), which lead to significant synaptic impairment,
inflammation, and progressive cognitive decline (Citron, 2010;
Karch et al., 2014). Late-onset AD (LOAD), in which symptoms
typically arise after age 65, is the most common form of AD and
accounts for approximately 98% of cases (Isik, 2010). Early-onset
AD (EOAD, also known as familial AD or FAD), accounts for
∼2% of AD cases, arises at ages <65, and results from a single
inherited mutation, typically in the amyloid precursor protein
(APP), Presenilin 1 (PSEN1), or Presenilin 2 (PSEN2) genes
(Dai et al., 2018).
Transgenic animal models have been critical for
understanding the development and progression of AD
(Jankowsky and Zheng, 2017). Owing to the similarities in
disease presentation between sporadic LOAD and inherited
EOAD and the lack of understanding of the genetic causes of
LOAD, known EOAD mutations, such as those observed in
APP and PSEN1/2 have been used to develop transgenic mouse
models for the study of both LOAD and EOAD (LaFerla and
Green, 2012). While transgenic models have been instrumental
in understanding AD mechanisms and risk factors, they are
limited in the degree of characteristics displayed in comparison
with AD in humans, and the full spectrum of AD effects has
yet to be recapitulated in a single mouse model (Dodart et al.,
2002; Duyckaerts et al., 2008; Porquet et al., 2015; Jankowsky and
Zheng, 2017). This incomplete development of AD pathology in
EOAD models likely contributes significantly to the difficulty in
translating therapeutics developed in EOAD mice to humans in
clinical trials to date. Despite promising advances, no effective
treatment has been established for AD (Cavanaugh et al., 2014;
Cummings et al., 2014, 2019).
The Model Organism Development and Evaluation for
Late-Onset Alzheimer’s Disease (MODEL-AD) consortium was
assembled by the National Institute on Aging (NIA) to develop
more robust animal models of AD with increased relevance to
human disease, standardize the characterization of AD mouse
models, improve preclinical testing in animals (Sukoff Rizzo
et al., 2020), and establish clinically relevant AD biomarkers,
among other aims toward enhancing the translational value of
AD models in clinical drug design and treatment development
(Oblak et al., 2020). The MODEL-AD consortium creates
and comprehensively characterizes novel mouse models to
help researchers select the most appropriate mouse for their
therapeutic studies and provide relevant measures and protocols
to assay AD-like phenotypes in appropriate therapeutic windows
(Oblak et al., 2020). It is hoped that the development of
more clinically appropriate AD mice and a more in-depth
understanding of the phenotype of existing AD mouse models
available to the AD research community will facilitate improved
translatability from mouse models to human clinical trials.
To this end, the Indiana University/Jackson
Laboratory/University of Pittsburgh (IU/JAX/Pitt) MODEL-AD
Center has conducted an exhaustive phenotyping study of
the commonly used 5XFAD mouse model to establish and
validate a characterization pipeline that will ultimately be
used to comprehensively phenotype new mouse models of
AD. The 5XFAD transgenic mouse was developed in 2006
and overexpresses human APP with three FAD mutations
[the Swedish (K670N, M671L), Florida (I716V), and London
(V7171) mutations] and human PSEN1 with two FAD mutations
(M146L and L286V) (Oakley et al., 2006). The expression of
both transgenes is regulated by neural-specific elements of the
mouse Thy1 promoter to drive their overexpression specifically
in brain neurons (Moechars et al., 1996). Understanding the
phenotypic changes in the 5XFAD mouse enhances the utility
of the model for developing clinical interventions, including
enhanced appreciation of its limitations and the time point(s) at
which therapeutics can be appropriately evaluated in this model
in the context of translatability.
Here, the IU/JAX/Pitt MODEL-AD Center presents a
systematic and comprehensive phenotypic analysis of the 5XFAD
mouse congenic on the C57BL/6J (B6) background at age
4, 6, and 12 months with a comparison between male and
female mice relative to age-matched controls, including the
characterization of regional Aβ deposition, proinflammatory
marker expression, aging-related frailty, metabolic health (level
of cholesterol, lipoprotein, and glucose), behavioral testing
response, gene expression via RNA-seq, and brain electrical
activity via electroencephalogram (EEG) analysis. All data and
standard operating procedures (SOPs) are available through the
AD Knowledge Portal1.
MATERIALS AND METHODS
5XFAD Transgenic Mouse Model
5XFAD transgenic mice overexpress the following five FAD
mutations: the APP(695) transgene harbors the Swedish (K670N,
M671L), Florida (I716V), and London (V7171) mutations, and
the PSEN1 transgene harbors the M146L and L286V FAD
mutations. The 5XFAD line was made congenic on the C57BL/6J
background in 2011 to minimize concerns related to allele
segregation and the high variability of the original hybrid
background. 5XFAD mice exhibit amyloid deposition, gliosis,
and progressive neuronal loss accompanied by cognitive and
motor deficiencies, recapitulating many of the features of human
AD. NFTs are not typically present in the 5XFAD model (Oakley
et al., 2006), however, indicating a significant difference between
the AD pathology of this model and human disease.
Animal Housing Conditions at Indiana
University and the Jackson Laboratory
Male hemizygous 5XFAD mice (MMRRC stock #: 34848) were
crossed with female C57BL6/J mice (JAX stock #: 000664) to
maintain the 5XFAD and non-transgenic WT colonies at Indiana
University and The Jackson Laboratory. Up to five mice were
housed per cage with Aspen SaniChip bedding and ad libitum
LabDiet R© 5K52/5K67 (6% fat) feed. The colony room was kept
1https://adknowledgeportal.synapse.org/
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on a 12:12 L:D schedule with the lights on from 7:00 am to
7:00 pm daily. Transgenic and WT mice were initially ear-
punched for identification; following genotyping, mice were
identified with p-chip (PharmaSeq) microchips placed at the
base of the tail. Both male and female littermate mice aged
4, 6, and 12 months old were used for this study. These ages
reflect early disease state (4 months), moderate disease state
(6 months), and late disease state (12 months). In all cases, non-
transgenic littermates were used as controls. All procedures were
approved by the Institutional Animal Care and Use Committees
at the Indiana University, The Jackson Laboratory, and the
University of Pittsburgh.
Animals and Housing Conditions at the
University of Pittsburgh
Adult male and female 5XFAD mice (MMRRC stock #: 34848)
and non-transgenic C57BL/6J controls (JAX stock #: 000664)
were received from The Jackson Laboratory at approximately
8 weeks of age. Mice were group-housed within sex and genotype
(n = 3–4 per cage) prior to surgical procedures, after which
the animals were single-housed to prevent damage to the EEG
implants by other cagemates. The housing rooms within the
AAALAC-certified vivarium at the University of Pittsburgh
consisted of ventilated caging and an automated watering system
with room temperature controlled at a setting of 22 ± 2◦C
and humidity at 50 ± 10%. The facility was on a 12:12 L:D
schedule (lights on at 7:00 am). Housing cages contained coarse
certified Aspen Sani-chip bedding (PJ Murphy, Mount Jewett, PA,
United States) and enrichment in the form of nestlets (Ancare
Corp., Bellmore, NY, United States) and translucent domes
(Braintree Scientific Inc., Braintree, MA, United States). Lab Diet
5P76, irradiated chow (Lab Diet, St. Louis, MO, United States)
was available ad libitum throughout all procedures.
Surgical Procedures for EEG Studies at
the University of Pittsburgh
Mice between 10 and 11 months of age, two-channel telemetric
transmitters [HD-X02; Data Sciences International (DSI), New
Brighton, MN, United States] were subdermally implanted near
the dorsal aspect of the rear flank. Each channel consisted of
two wire leads that run under the skin to the head and neck
of the mouse. Animals were anesthetized using isoflurane in
an anesthetic chamber (Compac 5, VetEquip, Livermore, CA,
United States), hair was shaved from the top of the head, and
ophthalmic ointment (Artificial Tears, generic) was applied to the
eyes before the mice were secured in a stereotaxic frame (Model
940, David Kopf Instruments, Tujunga, CA, United States)
equipped with a gas anesthesia nosecone (Kopf 923B) and
rubberized zygoma ear cups (Kopf 921). Body heat was regulated
using delta-phase isothermal pads (Braintree Scientific, Braintree,
MA, United States). A stable plane of anesthesia was maintained
throughout the procedure and verified at least every 15 min
by the toe-pinch reflex. Once the mice were secured, the skin
over the dorsal aspect of the shoulders to behind the eyes
was sanitized using iodine and isopropyl alcohol before making
a dorsal midline incision from just behind the eyes to the
scapulae. The exposed skull was completely cleared of blood
and tissue and further cleaned with 3% hydrogen peroxide.
This cleaning process is critical to ensure the bonding of the
dental acrylic used to the secure wire leads to the skull. For
cortical EEG, two small burr holes were drilled at AP: +1.0,
ML: ±1.0 and AP: −2.0, ML: ±1.0, with ML coordinates
opposing, counterbalanced by animal. The ends of the wires
were stripped, and one lead was placed through each burr
hole so as to touch, but not penetrate, the dura. The wires
and skull were then covered in glass ionomer dental acrylic
(Integrity A2, Dentsply Sirona, Charlotte, NC, United States). For
neck electromyography (EMG), stripped wires from the second
channel were inserted under the neck muscle and secured on each
side by non-absorbable sutures (Ethilon Black Monoflament,
Ethicon Inc., Somerville, NJ, United States). The animal was
then removed from the stereotaxic frame and the incision was
closed with non-absorbable sutures and sterilized with triple-
antibiotic ointment. Fifteen minutes prior to the end of the
procedure, animals received a subcutaneous 5 mg/kg dose of
carprofen for prophylactic analgesia. The animals were left to
recover on an isothermal heating pad in a clean home cage
until the righting reflex was restored, at which time the animals
were returned to the vivarium. Animals all received daily post-
operative carprofen for a minimum of 48 h or as needed to treat
acute pain. No animals in this cohort required post-operative
carprofen for more than 72 h. Sutures were removed 7–9 days
post-operatively.
EEG Recording Procedures
Electroencephalogram recordings took place 12–14 days
following implantation. Cohorts of eight mice, divided by sex,
were recorded in separate sessions 1 week apart, with males
recorded in cohort 1 and females in cohort 2. Each session was
recorded continuously over 72 h, beginning and ending in the
afternoon. Animals were brought into the testing room 1 h before
recording procedures began. Wire chow holders were removed
from the cages to allow for unobscured video monitoring, with
chow and HydroGel (Clear H2O, Portland, ME, United States)
available ad libitum in the cage. Implants were activated in each
mouse and the home cage was placed on top of the DSI receiver
before the recordings began. EEG and EMG data were sampled
continuously at 500 Hz, and activity and temperature were
sampled at 1 Hz using DSI Ponemah software. Each recording
was time-locked to a video camera interfaced with Noldus Media
Recorder software (Noldus, Leesburg, VA, United States). Lights
in the testing room were timed such that only red light was
present between 7 pm and 7 am to allow for video recording
during the animals’ inactive (dark) period. Animals were left
undisturbed during the recording session aside from daily health
and food monitoring.
EEG Quantification and Statistical
Analysis
Analysis of spike-wave activity was conducted using DSI
NeuroScore software. Recordings were initially band-pass filtered
between 0.5 and 80 Hz with a power-line filter at 60 Hz. Epochs
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of seizure-related spike-wave discharge were autonomously
identified by the software according to the following parameters:
dynamic threshold: 3–20 times baseline, spike duration: 1–200 ms
spike interval: 0.05–0.6 s, train duration minimum: 0.5 s, train
Join Interval: 1 s, minimum four spikes per train associated with
behavioral arrest in the video feed. Sleep stages were quantified
using SleepSign for Animals (Kissei-Comtec, Matsumoto City,
Nagano Prefecture, Japan) by comparing the delta (0.5–4 Hz)
and theta (4–8 Hz) power ratio during epochs where EMG
activity was below a threshold set for each animal according to
its baseline (generally 30–50 µV), indicating the absence of tone
in the neck muscles, and activity counts were zero. A delta ratio
above 0.4 during inactive EMG was quantified as slow-wave sleep
(SWS), whereas a theta ratio above 3 during these epochs was
quantified as paradoxical sleep. Power band distribution values
were derived using fast Fourier transform during each wake-
sleep stage. Values were plotted, and effects of genotype and sex
were analyzed by ANOVA with Tukey’s multiple comparison
tests using Prism 8 statistical software (GraphPad, San Diego,
CA, United States). A significance level of p < 0.05 was used
for all measures.
Perfusion and Preparation of Blood and
Tissue Samples
Mice at Indiana University and The Jackson Laboratory
were anesthetized to the surgical plane of anesthesia with
tribromoethanol at 4, 6, or 12 months of age. Under complete
anesthesia, animals were euthanized by decapitation and perfused
through the heart with ice-cold PBS. Trunk blood and brain tissue
were collected immediately after euthanasia. Trunk blood was
centrifuged for 15–20 min at 4◦C at 14,500 RPM, and the plasma
was stored at −80◦C. At the University of Pittsburgh, mice were
anesthetized with isoflurane and blood was collected followed
by decapitation.
The right brain was snap-frozen for the preservation of RNA
for gene expression studies. Total RNA was extracted using
Trizol (Invitrogen, CA, United States), and mRNA was purified
using biotin-tagged poly dT oligonucleotides and streptavidin-
coated magnetic beads. Quality was assessed using a NanoDrop
(Fisher Scientific).
Blood Plasma Analysis
Blood was collected from non-fasted mice aged 4, 6, or
12 months. Mice were anesthetized, and blood was extracted by
left ventricle cardiac puncture with a 25 g EDTA-coated needle
before PBS perfusion. Approximately 500 mL of whole blood was
transferred to a MAP-K2 EDTA Microcontainer (BD, Franklin
Lakes, NJ, United States) on ice and centrifuged at 4◦C at 4388× g
in a pre-chilled ultracentrifuge for 15 min. Without disturbing
the red blood cell fraction, serum supernatant was pipetted into
a chilled cryovial with a p200 tip and immediately snap-frozen
on dry ice for 10 min. Samples were stored at −80◦C and
later thawed for analysis of glucose, total cholesterol, low-density
lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride,
and non-essential fatty acid (NEFA) levels with the Siemens
Advia 120 (Germany).
Tissue Vision Whole-Brain Imaging and
Quantification of Plaque Progression
Mice were given an intraperitoneal injection of methoxy-X04
(5 mg/kg) to label amyloid plaques. Twenty-four hours after
injection, mice were euthanized by injection of ketamine/xylazine
(0.1 mL/10 g) and sequentially perfused with 1× PBS and 4%
PFA. Intact brains were dissected and post-fixed in 4% PFA
for 12–24 h at 4◦C. Whole-brain serial two-photon (STP)
tomography imaging was performed using a TissueCyte 1000
(TissueVision, Inc.) (Ragan et al., 2012). Brain samples were
imaged at 780 nm with 220 mW measured at the objective, and
emitted fluorescence was captured across three channels (ch1:
560–680, ch2: 500–560, and ch3: 400–500 nm). Methoxy-X04
fluorescence was predominantly identified in channel 3. One
hundred and forty serial block-face images were acquired at
100 µm spacing for each brain at ∼1.4 µm/pixel XY sampling.
Automated segmentation of the fluorescent signal from
methoxy-X04 labeled plaques across all sections was performed
by local threshold-based segmentation. The relative signal
intensity between the tissue autofluorescence signal identified in
channel 1 and the methoxy-X04 signal identified in channel 3
was first computed by channel subtraction to remove the local
background autofluorescence and identify the methoxy-X04
signal. A manually defined threshold was then applied to the
background-subtracted methoxy-X04 signal to minimize false
positives and generate a plaque mask for each section. This
background subtraction also reduced broad-spectrum false
positive signal intensities identified across all three channels
often identified around the olfactory bulbs. The imaging and
segmentation parameters were held constant across all samples
and all ages (2 months – eight females, eight males; 3 months –
seven females, eight males; 4 months – eight females, six males;
6 months – eight females, five males). To map brain regional
plaque densities, the Allen Brain Reference Atlas was registered
onto each brain sample using the Allen Mouse Brain Common
Coordinate Framework v3 (CCFv3) (Wang et al., 2020). Briefly,
the 10 µm average template brain from the CCF was registered to
a 10× down-sampled version (14 µm × 14 µm × 100 µm XYZ)
of each brain sample using a multi-resolution coarse-to-fine
linear to non-linear series of transformations (Ragan et al., 2012;
Kuan et al., 2015), and the corresponding Atlas Annotations
were then registered using the computed transform matrix.
The masked plaque density (fractional area) was mapped for
each brain region across sections by computing the ratio of
total masked pixels to total region pixels across all sections
after up-sampling of the atlas annotation section to the full
resolution STP datasets.
Spatial Proteomics Using NanoString
GeoMx Spatial Profiling
Hemibrains were embedded in paraffin and sectioned at 8 µm.
Staining was carried out according to the manufacturer protocol.
Microglia, astrocytes and plaques were labeled with IBA-1,
GFAP and pan-amyloid antibodies, respectively (NanoString,
Seattle, WA, United States). Nuclei were identified by staining
with the nucleic acid-binding fluorescent dye, SYTO 13
(Thermo). Amyloid plaques were selected by visual inspection.
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Using NanoString’s GeoMxTM Digital Spatial Profiler system
to immunostain for AD, PD, autophagy and glial cell relevant
proteins, amyloid-positive plaques were identified in the
cortex, hippocampus, and cerebellum. These selected areas
were illuminated individually via UV light on GeoMx DSP,
photocleaving the oligonucleotides present within each region
of interest (ROI). The oligonucleotides were collected on
GeoMx DSP in a 96-well microwell plate. Individual microwells
containing the collected photocleaved oligonucleotides from each
spatially resolved ROI were then hybridized to four-color, six-
spot optical barcodes, and analyzed on the nCounter R© platform,
resulting in distinct spatially mapped counts that correspond to
the antibodies from which the tags were cleaved. Digital counts
were normalized with internal controls for system variation and
then normalized to area and background.
Homogenization and Protein Extraction
Each hemibrain was weighed prior to homogenizing in tissue
protein extraction reagent (T-PER; Thermo Scientific; 1 mL
per 100 mg of tissue weight) supplemented with protease and
phosphatase inhibitors cocktail (Sigma-Aldrich). Total protein
concentration was measured using bicinchoninic acid (BCA;
Pierce). Hemibrain lysates were then aliquoted and kept in
the −80◦C freezer for long-term storage. Following tissue
homogenization, the DEA extraction of the soluble components
was performed as previously reported (Casali and Landreth,
2016). The primary supernatant was utilized to analyze the
content of proinflammatory cytokines, while the soluble DEA
components were used for the Aβ species analysis.
Cytokine Panel Assay
Mouse hemibrain samples were assayed in duplicate using
the MSD Proinflammatory Panel I (K15048D; MesoScale
Discovery, Gaithersburg, MD, United States), a highly sensitive
multiplex enzyme-linked immunosorbent assay (ELISA). This
panel quantifies the following 10 proinflammatory cytokines in
a single small sample volume (25 µL) of supernatant using an
electrochemiluminescent detection method (MSD): interferon γ
(IFN-γ), interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12p70, IL-13, and tumor necrosis factor α (TNFα). The mean
intra-assay coefficient for each cytokine was <8.5%, based on the
cytokine standards. Any value below the lower limit of detection
(LLOD) for the cytokine assay was replaced with 1/2 LLOD of the
assay for statistical analysis.
Aβ Species Assay
The plasma samples and soluble (DEA) components from
hemibrain samples were assayed in duplicate using MSD Aβ
Peptide Panel I (K15200E; MSD). Following the manufacturer’s
guidelines, the Aβ species (Aβ40 and Aβ42) were quantified from
plasma and soluble component of hemibrain lysates using an
electrochemiluminescent detection method (MSD). The levels of
Aβ species from the assay were used for statistical analysis.
Magnetic Resonance Imaging
To obtain high-contrast gray matter images, at least 2 days prior
to PET imaging, mice were induced with 5% isoflurane in medical
oxygen, placed on the head coil, and anesthesia was maintained
with 1–3% isoflurane for scan duration. High-resolution T2-
weighted (T2W) magnetic resonance imaging (MRI) images
were acquired using a 3T Siemens Prisma clinical MRI scanner
outfitted with a dedicated 4-channel mouse head coil and bed
system (RAPID MR, Columbus, OH, United States). Images
were acquired using a SPACE3D sequence using the following
acquisition parameters yielding 0.18 mm × 0.18 mm × 0.2 mm
resolution images: TA: 5.5 min; TR: 2080 ms; TE: 162 ms; ETL:
57; FS: On; Ave: 2; Excitation Flip Angle: 150; Norm Filter:
On; Restore Magnetization: On; Slice Thickness 0.2 mm: Matrix:
171 × 192; and FOV: 35 mm × 35 mm. After the imaging
period, mice were returned to their warmed home cages and
allowed to recover.
Radiopharmaceuticals
Regional brain glycolytic metabolism was monitored using
2-[18F]-fluoro-2-deoxy-D-glucose ([18F] FDG), which was
synthesized, purified, and prepared according to established
methods (Yu et al., 2006). Similarly, (E)-4-(2-(6-(2-(2-(2-([18F]-
Fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl
benzenamine ([18F]-AV45) was synthesized, purified, and
prepared according to established methods (Yao et al., 2010).
In all cases, clinical unit doses ranging from 185 to 370 MBq
(5–10 mCi) were purchased from PETNet Indiana (PETNET
Solutions Inc.).
In vivo Imaging
Mice were anesthetized with 5% isoflurane gas and maintained
at anesthetic plane with 1–3% isoflurane throughout imaging.
Mice were injected IV with 3.7–11.1 MBq (100–300 uCi) [18F]-
AV45, and IV or IP with [18F]-FDG at a volume <10% of
body weight and allowed 30 min of uptake in an isothermal
cage. In all cases, mice receiving [18F]-FDG were fasted for a
minimum of 12 h prior to tracer administration. Mice were
scanned on the IndyPET3 (Rouzes et al., 2004) scanner for
15 min for both [18F]-AV45 and [18F]-FDG. Calibrated, decay,
and scatter-corrected PET images were reconstructed into a
single-static image volume with a minimum field of view of
60 mm using filtered-back-projection according to published
methods (Soon et al., 2007), and converted from native NetCDF
to an Analyze 12-compatible format via a local bash script
prior to analysis.
Cryotomy
After PET imaging, animals were euthanized via rapid
decapitation, and brains were removed, bisected, and snap-frozen
on dry ice before embedding in OCT in cryomolds. Brains were
sectioned at 20 µm with a Leica 1850 or CM1860 Cryotome, with
6 per slide per bregma ROI. The bregma targets of 0.38, −1.94,
−3.8, −5.88 based on stereotactic mouse brain coordinates
(Franklin and Paxinos, 2013) were selected to cover the following
ROIs: Corpus Callosum, Striatum, Cingulate Cortex, Motor
Cortex, Somatosensory Cortex, Dysgranular Insular Cortex,
Medial Septum, Hypothalamus, Hippocampus, Retrosplenial
Dysgranular Cortex, Auditory Cortex, Dorsintermed Entorhinal
Cortex, Thalamus, Temporal Association Cortex, Visual
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Cortex, and Cerebellum. One half of the brain is utilized
for autoradiography, the other half is used for IHC as a
tertiary confirmation.
Autoradiography
Standards for calibration were prepared using twofold serial
dilutions of PET tracer in 3.2% low melt agarose, 4% sucrose,
0.2% gelatin. Aliquots (∼30 µL) were dotted into cryomolds
and allowed to solidify at room temperature. OCT compound
was added, and standards were frozen and cut at the same
thickness as the brain sections. An additional ∼20 µL aliquot
was pipetted into a 7 mL scintillation tube filled with scintillation
fluid and measured on a Beckman LSC 6500 for 15–30 s using
the full spectrum window. These data were used to calculate the
standard curve for each animal and were converted to Bq/mL
according to laboratory SOPs. Brain sections mounted on slides
were placed on cardboard along with the standards and exposed
overnight to the phosphorimager screen before imaging on the
GE Typhoon FLA7000IP.
Image Analysis
All PET and MRI images were co-registered using a ridged-
body mutual information-based normalized entropy algorithm
with 9◦ of freedom and mapped to stereotactic mouse brain
coordinates using Analyze 12 (AnalyzeDirect, Stilwell, KS,
United States). Post-registration, 56 bilateral regions were
extracted via brain atlas and averaged to yield 56 unique volumes
of interest (27 bilateral regions) that map to the following key
cognitive and motor centers: Agranular Insular Cortex; Auditory
Cortex; Caudate Putamen; Cerebellum; Cingulate Cortex;
Corpus Callosum; Dorsolateral Orbital Cortex; Dorsintermed
Entorhinal Cortex; Dysgranular Insular Cortex; Ectorhinal
Cortex; Fornix; Frontal Association Cortex; Hippocampus;
Lateral Orbital Cortex; Medial Orbital Cortex; Parietal Cortex;
Parietal Association Cortex; Perirhinal Cortex; Prelimbic
Cortex; Primary Motor Cortex; Primary Somatosensory Cortex;
Retrosplenial Dysgranular Cortex; Secondary Motor Cortex;
Secondary Somatosensory Cortex; Temporal Association
Cortex, Thalamus; Ventral Orbital Cortex; and Visual Cortex.
For autoradiographic analysis, tracer uptake was quantified
on hemi-coronal sections by manually drawing regions
of interest for 17 regions of interest (namely, Auditory
Cortex, Caudate Putamen, Cerebellum, Cingulate Cortex,
Corpus Callosum, Dorso-intermediate Entorhinal Cortex,
Dysgranular Insular Cortex, Ectorhinal Cortex, Hippocampus,
Hypothalamus, Medial Septum, Primary Motor Cortex, Primary
Somatosensory Cortex, Retrosplenial Dysgranular Cortex,
Temporal Association Cortex, Thalamus, and Visual Cortex)
on a calibrated phosphor screen at bregma 0.38, −1.94,
and −3.8 mm using MCID (InterFocus Ltd.). Standardized
Uptake Value Ratios (SUVR) relative to the cerebellum were
computed to permit dose and brain uptake normalization for




s, R, g, a
)
= (R(s, g, a))/(C(s, g, a)) (1)
where, s, g, a, R, and C are the subject, genotype, age,
region/volume of interest, cerebellum region/volume of interest.
Principal component analysis was performed to provide data
reduction for all PET and autoradiography regions. Consensus
regions of interest were selected, which explained 80% of
the variance observed across all regions studied. In all cases,
PCA selected regions/volumes of interest were analyzed for
differences with time and genotype using a two-way ANOVA
(Prism, GraphPad Inc.) where p < 0.05 was considered
statistically significant.
Behavioral Tests
Behavioral tests were conducted in the Mouse Neurobehavioral
Phenotyping Facility at The Jackson Laboratory as previously
described (Sukoff Rizzo et al., 2018) with a minimum of a 1–2 day
rest period between tests that were conducted in the following
order: frailty assessment with core body temperature recording,
open field test, spontaneous alternation, rotarod, and home cage
wheel running. On each test day, subjects were transported from
the adjacent housing room into the procedure room, tails were
labeled with a non-toxic permanent marker with the assigned
subject ID number for ease of identification, and subjects were left
to acclimate to the testing environment for a minimum of 60 min
before testing. Between subjects, all testing arenas were sanitized
with 70% ethanol solution and dried prior to introducing the next
subject. Lighting in the testing rooms was consistent with the
housing room (∼500 lux), except for the cognitive tests, which
were conducted under ambient lighting (∼30–50 lux). Wheel
running was conducted under standard housing conditions with
a 12:12 L:D cycle. At a minimum of 5 days after the conclusion
of behavioral testing, tissue was harvested as per MODEL-AD
protocols (see text footnote 1).
Home Cage Wheel Running
Subjects were individually housed with a wireless running wheel
(Med Associates Inc., Fairfax, VT, United States; Cat# ENV-
047) and left undisturbed for three consecutive nights except for
daily welfare checks. Data were analyzed in 1 min epochs and
calculated as the cumulative time spent running and the average
total distance traveled over 30 min periods.
Frailty Assessment
The frailty assessment was conducted as previously described
(Sukoff Rizzo et al., 2018) to assess the spectrum of aging-related
characteristics and determine if 5XFAD mice demonstrated
alterations in normal healthy aging relative to controls. Following
acclimation to the testing room as described above, subjects
were individually evaluated for the absence, presence, and
severity of 26 characteristic traits and reflexes and scored
as 0, 0.5, or 1 by a trained observer who was blind to
genotype/age. The following were assessed: alopecia, loss of fur
color, dermatitis/skin lesions, loss of whiskers, coat condition,
piloerection, cataracts, eye discharge/swelling, microphthalmia,
nasal discharge, rectal prolapse, vaginal/uterine/penile, diarrhea,
vestibular disturbance, vision loss by visual placing upon the
subject being lowered to a grid, menace reflex, tail stiffening,
impaired gait during free walking, tremor, tumors, distended
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abdomen, kyphosis, body condition, breathing rate/depth,
malocclusions, and righting reflex. Subjects were evaluated for
each measure independently and a cumulative score of all
measures was calculated with a maximum score of 26 (frailty
index). Normal healthy aging is indicated by age-dependent
increases in the cumulative frailty score.
Core Body Temperature
Core body temperature was recorded before the conclusion
of the frailty assessment with a glycerol-lubricated thermistor
rectal probe (Braintree Scientific product# RET 3; measuring
3/4′′ L0.028 dia.0.065 tip) inserted ∼ 2 cm into the rectum
of a manually restrained mouse for approximately 10 s. The
temperature was recorded to the nearest 0.1◦C (Braintree
Scientific product# TH5 Thermalert digital thermometer).
Reductions in core body temperature are typical with aging
and inversely correlate with frailty score, indicating morbidity.
Increases in body temperature relative to controls may indicate
hyperthermic responses induced by stress or inflammation.
Open Field Test
Versamax Open Field Arenas (40 cm × 40 cm × 40 cm;
Omnitech Electronics, OH, United States) were housed in sound-
attenuated chambers with lighting consistent with the housing
room. Following acclimation to the testing room as described
above, mice were placed individually into the center of the arena,
and infrared beams recorded distance traveled (cm), vertical
activity, and perimeter/center time. Data were collected in 5 min
intervals for 60 min.
Spontaneous Alternation
Mice were acclimated to the testing room under ambient lighting
conditions (∼50 lux). A clear polycarbonate y-maze (in-house
fabricated; arm dimensions 33.65 cm length, 6 cm width, 15 cm
height) was placed on top of an infrared reflecting background
(Noldus, Netherlands), surrounded by a black floor-to-ceiling
curtain to minimize extra-maze visual cues. Mice were placed
midway in the start arm (A) facing the center of the y for an 8-min
test period. The sequence of entries into each arm was recorded
via a ceiling-mounted infrared camera integrated with behavioral
tracking software (Noldus Ethovision XT). Percent spontaneous
alternation was calculated as the number of triads (entries into
each of the three different arms of the maze in a sequence of
three without returning to a previously visited arm) relative to
the number of alteration opportunities.
Rotarod Test for Motor Coordination
An accelerating rotarod (Ugo-Basile; model 47600) was used for
this test. Lighting in the testing room was consistent with the
housing room. Following acclimation to the testing room as
described above, mice were placed on the rotating rod (4 RPM),
which accelerated up to 40 RPM over 300 s. Each mouse was
subjected to three consecutive trials with an approximate 1-
min inter-trial interval to clean the rod between trials. Latency
to fall (seconds) was measured. Subjects that fell upon initial
placement on the rod before acceleration started were scored as
0 s for that trial.
Analysis of Behavioral Data
Data were quality-controlled blind prior to analysis to exclude
data from mice that could not be tested or failed to meet inclusion
criteria as noted above, or data unavailable due to equipment
failures and escape episodes. No subjects were considered
mathematical outliers or excluded based on mathematical
determination (e.g., 2 SD ± mean). Data were analyzed
under coded genotypes (A, B, C, etc.) within sex, as one-
way or two-way ANOVA as appropriate versus sex- and age-
matched WT controls.
RNA-Seq
The RNA from a total of 36 5XFAD and 36 littermate control
mice was sequenced; 6 mice per sex, genotype, and timepoint.
Sequencing libraries were constructed using TruSeq DNA V2
(Illumina, San Diego, CA, United States) sample prep kits
and quantified using qPCR (Kapa Biosystems). The mRNA
was fragmented, and double-stranded cDNA was generated
by random priming. The ends of the fragmented DNA were
converted into phosphorylated blunt ends. An “A” base was added
to the 3′ ends. Illumina R©-specific adaptors were ligated to the
DNA fragments. Using magnetic bead technology, the ligated
fragments were size-selected, then a final PCR was performed to
enrich the adapter-modified DNA fragments since only the DNA
fragments with adaptors at both ends will amplify.
Sequencing
Libraries were pooled and sequenced by the Genome
Technologies core facility at The Jackson Laboratory. All 36
samples were sequenced on an Illumina HiSeq 4000 using HiSeq
3000/4000 SBS Kit reagents (Illumina), targeting 30 million read
pairs per sample. Samples were split across multiple lanes for
Illumina HiSeq; once the data were obtained, the samples were
concatenated to produce a single file for paired-end analysis.
Data Processing
RNA-Seq data were processed with our parallelized and
automatic pipeline. Reads were quality-trimmed and filtered
using the Trimmomatic tool. Reads passing the quality filtering
were mapped to the mm10 reference genome augmented
with transgene sequences using the RNA-seq aligner STAR
(Dobin et al., 2013). To quantify human APP and PSEN1
transgene expression, we created a chimeric mouse genome
by concatenating human APP (Chromosome 21: 25880550–
26171128) and PSEN1 (Chromosome 14: 73136418–73223691)
gene sequences into the mm10 genome (Ensembl Genome
Reference Consortium, build 38) as separate chromosomes
(labeled chromosomes 21 and 22). Subsequently, we added gene
annotations for hAPP and hPSEN1 genes in the resulting gtf
file. A STAR index was built from this mouse chimeric genome
sequence for alignment, and STAR-generated coordinate-sorted
BAM files were mapped to the chimeric mouse genome using this
index. The HTSeq-count package was used to obtain raw read
counts, and the RSEM software package was used to estimate
expression levels for all genes as transcripts per million (TPM)
(Dobin et al., 2013). Genes with zero counts in more than 75%
of samples were filtered out before applying the upper quantile
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normalization method to the TPM, which were log-transformed
for downstream analysis.
Principal Component Analysis
We analyzed 72 RNA-Seq samples originating from the 5XFAD
transgenic and B6 non-carrier littermate control mice of
different ages. First, we implemented the variance stabilizing
transformation (VST) function of DESeq230 to normalize the
raw read count data. We then used the biplot function in
R to assess the differences in sample distributions due to
genotype, age, and sex.
Differential Expression Analysis
Differential expression in mouse models was assessed using
the Bioconductor package DESeq2 (v1.16.1) (Love et al., 2014).
DESeq2 takes raw read counts obtained from HTSeq-count as the
input. The significance of differential expression was determined
by the Benjamini–Hochberg corrected p-values. The threshold
for significance was set to adjusted p < 0.05.
Generalized Linear Model
A generalized linear model (GLM) was used to identify
transcripts with differential expression as a function of sex,
genotype, and sex-genotype interaction for each age group. The
expression value of a gene E in log2 (TPM) was defined using the
following linear model:
E = β_0 + β_1 Sex + β_2 Genotype
+ β_12 Sex.Genotype + ε, (2)
where β_0 and ε represent average expression level for the
reference WT male mice and residual, respectively.
We used False Discovery Rate (FDR)-corrected p-value (q-
value) and R2 from the linear model to determine how well each
gene’s expression across the samples could be fit by the predictors
of the model, which were sex, genotype and sex-genotype
interaction. For each gene, the GLM returned an estimate for each
predictor’s effect size and corresponding significance. We used
a relatively permissive threshold (q-value < 0.25 and R2 > 0.3)
to identify transcripts potentially fit by the model. Taking the
WT as the reference genotype and male as the reference sex,
we extracted significant transcripts (p < 0.05) for genotype
(5XFAD), sex (female) and sex-genotype interaction (5XFAD
female) for each age group.
Functional Enrichment Analysis
Functional annotations and enrichment analysis were performed
using the R package clusterProfiler (Yu et al., 2012), with Gene
Ontology and KEGG pathway enrichment analyses performed
using the enrichGO and enrichKEGG functions, respectively.
The function compareCluster was used to compare enriched
functional categories of each gene module. The significance
threshold for all enrichment analyses was set to 0.05 using
Benjamini–Hochberg-adjusted p-values.
Comparison to Human Transcriptomes
Mouse transcriptomes were systematically compared to human
disease signatures from the Accelerating Medicines Partnership
in Alzheimer’s Disease (AMP-AD) studies (Wan et al., 2020).
We computed Pearson correlation between change in expression
(log fold change) for each gene in a given module with each
mouse model, sex, and age (Wagner et al., 2019; Preuss et al.,
2020). Correlation coefficients were computed using the cor.test






where Log2FC(h) is the log fold change in transcript expression
of human AD patients compared to control patients and
Log2FC(m) is the log fold change in expression of mouse
transcripts compare to age and sex-matched control mouse
models. Log2FC values for human transcripts were obtained
through the AD knowledge portal.
RESULTS
Cholesterol, Lipoprotein, and Glucose
Changes in 5XFAD Mice
Non-fasted plasma was collected at the termination of the
study from male and female 5XFAD and WT mice aged 4, 6,
and 12 months. Cholesterol levels, LDLs, HDLs, triglycerides,
non-essential fatty acids, and glucose levels were compared
(Figures 1A–F). Total cholesterol was lower in female 5XFAD
and WT mice than in male counterparts at all ages; however,
a significant difference in female total cholesterol was present
only between 4- and 12-month-old 5XFAD mice (Figure 1A).
In male mice, total cholesterol in 5XFAD versus WT mice was
not significantly different at 4 months of age, trended lower in
5XFAD mice at 6 months of age and was significantly lower
in 5XFAD mice at age 12 months of age (Figure 1A). Female
5XFAD and WT mice had higher LDL levels (Figure 1B), and
lower HDL levels (Figure 1C) than males, with no significant
difference observed between WT and 5XFAD in females in
either lipoprotein. In male mice, LDL and HDL levels were
significantly lower at 12 months of age than at 4 and 6 months
of age (Figures 1B,C) and HDL levels decreased significantly
between WT and 5XFAD mice at the 6- and 12-month time
points (Figure 1C). No significant differences were observed
in triglyceride levels across all tested groups (Figure 1D). At
12 months of age, WT male mice demonstrated elevated non-
essential fatty acids in comparison with 4-month-old WT mice,
and non-essential fatty acid levels were markedly decreased in
male 5XFAD at the same age (Figure 1E). Finally, glucose levels
in female WT mice were significantly elevated between the 4- and
12-month-old groups, which was mitigated in the 12-month-old
5XFAD mice (Figure 1F).
Hyperactivity Was the Most Robust
Behavioral Phenotype in 5XFAD Mice
In the open-field test, both male and female 5XFAD mice
demonstrated increases in total distance traveled and
corresponding reductions in total resting time, indicative of
hyperactivity (Figure 2A). This phenotype was observed both
at 6 and 12 months of age. Interestingly rearing behavior, as
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FIGURE 1 | Decreased total cholesterol and lipoproteins in 5XFAD males compared to wild-type males and decreased glucose levels in 5XFAD females compared to
wild-type females. Non-fasted plasma was collected at the termination of the study, and total cholesterol (A), low-density lipoproteins (B), high-density lipoproteins
(C), triglycerides (D), non-essential fatty acids (E), and glucose (F) levels were measured.
FIGURE 2 | Functional assessment reveals hyperactivity associated with changes in frailty score in 5XFAD mice. Hyperactivity was observed in 5XFAD mice
compared with controls was determined using open field and running wheels (A–D). There were increases in distance traveled, vertical and horizonal activity and
reductions in resting time. In the rotarod test (E), both male and female 5XFAD mice maintained their balance for a greater period of time than the age-and
sex-matched WT controls. Male and female 5XFAD mice and controls demonstrated aging-dependent increases in frailty scores from 6 months to 12 months of age
(F). 5XFAD male or female mice did not demonstrate deficits in percent alternation relative to age-and sex-matched controls at either 6 or 12 months of age (G).
measured by vertical activity counts, was significantly reduced
in 5XFAD mice relative to the controls, which may be a
consequence of increased total distance traveled, a measure
analyzed by horizontal activity (Figure 2B). While the open-field
test is limited to spontaneous activity in a novel environment
for only a 60 min period, hyperactivity was also more robustly
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reflected during home-cage wheel-running assessments, which
were conducted over the course of a 72-h period (Figure 2C).
Notably, both male and female 5XFAD mice demonstrated
significant increases in time spent on the wheel and averaged
significantly greater distances traveled relative to that of age-
and sex-matched WT controls, indicative of hyperactivity
(Figure 2D). In the rotarod test (Figure 2E), both male and
female 5XFAD mice maintained their balance for a greater
period of time than the age- and sex-matched WT controls.
This does not indicate that 5XFAD mice have impaired motor
coordination, but rather increased latency to fall, which has
been previously correlated with hyperactivity phenotypes in
mice (Wagner et al., 2019) and is in line with the hyperactivity
observed in the open-field and wheel-running assessments in
the present study.
Frailty Changes in 5XFAD Mice
Male and female 5XFAD mice and controls demonstrated aging-
dependent increases in frailty scores from 6 to 12 months of age
(Figure 2F). Notably, 5XFAD mice at both ages demonstrated
reductions in body weight relative to the age- and sex-matched
controls, similar to what others have previously found (Jawhar
et al., 2012). Reduced body weight is unlikely a result of the
weight loss observed in aged and “frail” C57BL/6J mice as other
traits associated with sarcopenia were not observed. It is more
likely that 5XFAD mice do not gain weight at the same rate as
WT controls, which may be related to their robust hyperactivity.
While 12 months is not necessarily considered “aged” for mice,
WT animals show the expected incremental changes across
a spectrum of aging-related traits as early as 12 months of
age. Interestingly, while the cumulative frailty score in 5XFAD
mice, which reflects the spectrum of subtle aging changes across
phenotypes, reflected a modest change at best relative to WT
controls; analysis of the percentage of subjects presenting with
specific aging traits at 12 months of age that were not observed
nor expected in controls revealed observations of tremor in
n = 4/12 (33.3%) 5XFAD males and n = 6/12 (50%) 5XFAD
females, and impaired righting reflex in n = 4/12 (33.3%) 5XFAD
males and n = 1/12 (8.33%) 5XFAD females at 12 months of age
(Figure 2F). Although these phenotypes were not 100% penetrant
in 5XFAD mice, they indicate an exacerbated aging phenotype of
disease-progression phenotype in these mice. Notably, core body
temperature was elevated in both male and female 5XFAD mice
relative to age-matched controls, which may be indicative of a
hyperthermic response induced by stress or inflammation, which
was observed in this model.
Lack of Reliable Cognitive Phenotypes in
5XFAD Mice in Spontaneous Alternation
Assays
Given the previously reported hyperactivity phenotype in 5XFAD
mice (Flanigan et al., 2014) that we have confirmed in the
present study, we selectively chose the spontaneous alternation
task (Figure 2G) to evaluate hippocampal working memory. This
test does not have the high level of motor confounds present in
other cognitive tests (e.g., the water maze, novel object, and fear
conditioning tests). Furthermore, since cognitive tests in mice
have failed to provide translational or predictive utility in the
clinic, we limited our resources to spontaneous alternation, which
has a minimal false-positive rate for cognitive deficits and has
highly consistent baselines across both male and female control
C57BL/6J mice (Tucker et al., 2016). Furthermore, alterations in
spontaneous alternation have been previously reported (Jawhar
et al., 2012). In the present studies, male and female C57BL6/J
controls demonstrated the expected range for percent alternation,
which was consistent across age and sex (49–52%). 5XFAD male
or female mice did not demonstrate deficits in percent alternation
relative to age- and sex-matched controls at either 6 or 12 months
of age (Figure 2G). While there were significant changes within
the 5XFAD phenotype in these cohorts between 6 and 12 months
of age, the directionality of those changes was opposite in
females and males. Interestingly, both male and female 5XFAD
demonstrated reductions in total arm entries at both 6 and
12 months of age relative to age- and sex-matched controls
during this 8 min test (Figure 2G), which may be reflective
of within-arm perseverative–hyperactive behavior. Importantly,
the abnormal activity phenotype did not confound the primary
outcome measure of spatial working memory in this test.
No Emergent Phenotype of Sleep or
Seizure Activity in 5XFAD Mice
Sleep and seizure activity were compared in male and female
5XFAD mice over a 72-h period (Figure 3), measuring sleep
phase distribution (Figures 3A,B) and spike-wave activity
(Figures 3C–F) during each activity period. A difference was
observed in the distribution of the sleep cycle of female mice
during the first inactive period following the movement of the
mice to the testing room; however, the sleep phase distribution
analysis did not reveal a significant difference between WT and
5XFAD mice of either sex in the time spent in each respective
sleep phase overall. No significant difference was observed in
spike-wave activity between any of the tested groups.
Lack of Seizure Activity and Sleep
Disturbances in 5XFAD
Overall, no phenotypic differences in EEG seizure markers were
identified in 5XFAD mice compared to the littermate controls.
No significant differences were found within any frequency
band during wake [Figure 3D, F (12, 60) = 0.9535], NREM
[Figure 3E, F(12, 60) = 1.054, p = 0.41], or REM sleep [F(12,
60) = 0.8458, p = 0.60]. C57BL/6J and 5XFAD female mice
displayed increased active [F(1, 12) = 24.16, p < 0.01] and
inactive [F(1, 12) = 15.99, p < 0.01] waking (Figure 3G) and
decreased active [F(1, 12) = 22.86, p < 0.01] and inactive [F(1,
12) = 10.29, p < 0.01] NREM (Figure 3H). In all mice, these
were the main effects and only differed individually compared
to C57BL/6J males. A simple main effect of decreased REM
sleep was observed in female mice [Figure 3I, F(3, 24) = 3.409,
p = 0.03], but no interaction was observed between individual
groups [F(3, 24) = 0.4180, p = 0.74]. No significant interactions
[F(6, 36) = 2.039, p = 0.09] or main effects [F(3, 36) = 2.539,
p = 0.07] were found for mean episode duration (Figure 3J).
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FIGURE 3 | No emergent phenotypes of sleep or spike-wave activity in 5XFAD mice. No emergent phenotypes of sleep or spike wave activity in 5XFAD mice. Sleep
and seizure activity was assessed by EEG in female and male 5XFAD mice (n = 4 per group). Example traces during epochs of wake (A), NREM sleep (B), and REM
sleep (C) are displayed across the top. No statistical differences in frequency are measured during wake (D), NREM (E), or REM (F). Analysis of sleep phase
distribution during each activity period throughout the 72 h recording does not reveal significant differences in time spent in each respective sleep phase. Increased
wake (G), and decreased NREM sleep (H) is witnessed in female mice during both activity phases compares to male controls. Differences in REM sleep (I) are not
seen. Mean duration of wake epochs are significantly increased in females compared to male controls (J). An example of a putative spike wave identified using pike
sorting criteria (K). No significant differences in spike wave activity (L), spike wave duration (M), or spikes per train (N), are identified for sex or genotype.
Post hoc analyses of these trend effects identified an increased
wake episode duration in female mice compared to male controls,
but no other effects were seen. No significant interaction [F(1,
12) = 0.32, p = 0.58] or main effect of sex [F(1, 12) = 1.64, p = 0.22]
or genotype [F(1, 12) = 2.22, p = 0.16] was detected in the number
of spike-wave events over the course of the recording. Females
exhibited greater spike train duration [F(1, 12) = 8.50, p = 0.01]
and spikes per event [F(1, 12) = 6.64, p = 0.02] compared to
those of males. However, this effect was irrespective of genotype
as neither interaction terms for duration [F(1, 12) = 0.13, p = 0.73]
nor spikes per train [F(1, 12) = 0.285, p = 0.60] differences were
significant. No main effects of genotype were detected for spike-
wave events [F(1, 12) = 2.22, p = 0.16], spike train duration F(1,
12) = 0.86, p = 0.37], or spikes per train [F(1, 12) = 0.62, p = 0.45].
Site Is the Greatest Predictor of
Microbial Differences
Previous studies have examined the microbiome of AD-related
mouse models and found microbial differences. In the present
study, we examined the 5XFAD mouse and WT controls over
multiple time points (ages 2–21 months) and across three sites.
The largest source of variability is site, meaning that the same
strains have different microbial profiles depending on where the
mice are housed (Supplementary Figures 1A–D). There were
few, if any, differences in microbiome composition between
5XFAD and WT within a center when both genotypes were
sampled. As this study was a survey of microbiome changes
within the 5XFAD mouse, it revealed useful information about
center differences and the similarity of 5XFAD and WT animals
when comparing animals across sites.
Genotype and Sex Are a Major Source of
Variation in Gene Expression Changes in
5XFAD Mice
Principal component analysis was used to compare the brain
transcriptome of male and female 5XFAD and WT mice at 4, 6,
and 12 months of age (Figure 4). The first principal component
accounted for 23% of the total variance and separated the mice by
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genotype into the 5XFAD and WT groups. The second principal
component accounted for 11% of the total variance and separated
male and female mice in both the 5XFAD and WT groups, with
each of the four groups clustering distinctly at all ages, indicating
sex-based molecular changes in both genotypes (Figure 4A).
Furthermore, the KEGG enrichment analysis comparison of
male and female 5XFAD and WT mice revealed that genes
with significantly upregulated expression in 5XFAD versus WT
mice overall had further elevated expression in female 5XFAD
mice (Figure 4B).
5XFAD Mice Display Transcriptomic
Changes Characteristics of AD
Gene expression changes in male and female 5XFAD versus WT
mice were compared with changes observed in human patients
with AD versus controls using AMP-AD modules grouped into
five previously identified consensus clusters that describe the
major functional groups of alterations observed in human AD
(Wan et al., 2020). Male and female 5XFAD mice display gene
expression alterations across all five consensus clusters, with the
most pronounced alterations observed in Consensus Cluster B,
which consists of immune system pathways (Figure 4C).
Whole Brain Imaging and Quantification
of Plaque Progression
To map the progression of brain-wide Aβ accumulation in
5XFAD mice, we utilized STP tomography to visualize the
spatial distribution of methoxy-X04 labeled Aβ plaques (Klunk
et al., 2002) across female and male cohorts at 2, 3, 4, and
6 months of age (Figure 5). Labeled plaques could be readily
identified throughout the brain (Figure 5A), and automated
analysis routines were developed to segment plaques and map the
spatial density across brain regions through registration to the
Allen Brain Reference Atlas (Oh et al., 2014; Figure 5B and see
section “Materials and Methods”). Labeled plaques were already
present at 2 months in both males and females, with the greatest
densities present in the hippocampal formation and subcortical
structures (Figure 5C), consistent with previous studies (Canter
et al., 2019). We observed an age-dependent accumulation in
plaque density across brain regions as has been observed in other
mouse models of AD (Whitesell et al., 2019). In both females
and males, region-specific accumulations were observed, with
the greatest densities occurring in the hippocampal formation,
cortical subplate, and thalamic regions (Supplementary Table 1).
5XFAD Mice Have Increased Glucose
Metabolism and Deposition of Aβ as
Evidenced by in vivo Imaging
To understand regional amyloid deposition (Figure 6) and
glycolysis (Figure 7), we performed in vivo PET imaging using
the [18F] tracers, AV45 and FDG, respectively, similar to what
has been done previously in the field (Girard et al., 2013;
Tang et al., 2016; Franke et al., 2020; Chang et al., 2021).
Amyloid deposition can be observed as early as 4 months in
regions involved in emotion and memory (orbital cortex, parietal
association cortices), as well as the thalamus and motor cortex
using PET (Figure 6A). The amyloid deposition was significantly
increased by 12 months of age (Figure 6B). Autoradiography,
a measure with 40× greater resolution and 100× greater
sensitivity, was used to confirm these findings (Figures 6C,D).
Glycolysis, as measured by [18F]-FDG PET, showed little changes
at 4 months of age (Figure 7A) and were generally confirmed
via autoradiography (Figure 7C); however, in select regions such
as the thalamus, [18F]-FDG uptake was decreased 5XFAD mice
when compared to WT controls as estimated by autoradiography
(Figure 7C). By 12 months of age, reduced glycolysis was
observed in both sexes using PET (Figure 7B) and was confirmed
via autoradiography (Figure 7D) in male mice, while reduced
glycolysis was observed in females in the auditory cortex. As a
tertiary measure of the PET imaging data, IHC was completed
on the half brains after in vivo imaging. ThioflavinS and IBA1
staining (data not shown) confirmed increased microgliosis in the
areas with amyloid deposition. Based on these findings, glycolysis
was altered in brain regions associated with sensory integration
and auditory function in 5XFAD mice when compared with WT
controls and was confirmed via post-mortem autoradiography.
5XFAD Mice Have Elevated Plasma and
Brain Aβ40 and Aβ42 and Proinflammatory
Cytokines
5XFAD mice demonstrate significantly elevated soluble Aβ40
and Aβ42 levels in the plasma and the soluble components
of the hemibrain lysates at 4, 6, and 12 months of age
in comparison with the levels observed in WT mice
(Supplementary Figure 2A). Additionally, the Aβ42/40 ratio
was significantly increased between 4, 6, and 12 months of age
in the soluble hemibrain fractions and plasma (Supplementary
Figures 2A,B). We also examined the neuroinflammatory
response to amyloid deposition and the level of proinflammatory
cytokines (IL-1β TNF-α, and KC/GRO) was significantly
elevated in 5XFAD hemibrain lysates during disease progression
(Supplementary Figure 2C).
Analysis of the Aβ Plaque
Microenvironment Using the Nanostring
GeoMx Platform Reveals Differences
Between Hippocampus and Cortex
To further identify differences between 4- and 12-month-old
5XFAD mice with respect to the Aβ plaque microenvironment,
we took advantage of the NanoString GeoMx platform to obtain
a detailed view of >40 proteins in the plaque microenvironment
simultaneously with digital quantitation and spatial resolution
(Figure 8). We selected the frontal cortex and hippocampus
from four mice per experimental group and analyzed one
concentric circle around multiple Aβ plaques per section. The
box plots demonstrated significant and differential changes in
multiple proteins between 4 and 12 months that are related
to the age-related deposition of amyloid and increased gliosis
in response to pathology in the cortex (Figure 8A) and
hippocampus (Figure 8B). More specifically, as expected, Aβ42
and APP levels are increased in 5XFAD mice compared to
controls at 4 months, and these changes are further increased
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FIGURE 4 | Transcriptomics identified genotype and sex being a major source of variation in between 5XFAD and WT mice and a positive correlation with most of
the functionally distinct AMP-AD modules. (A) The first principal component accounted for 23% of the total variance and separated 5XFAD samples from WT
animals. Female and male samples clustered distinctly at all ages in the second principal component (11% of total variance), suggesting the presence of sex-biased
molecular changes in animals. Female and male samples are shown in red and green colors, respectively. 5XFAD and WT controls are represented as circles and
triangles, respectively. Increasing point sizes represent the increasing age of the mice (4, 6, and 12 months, respectively). (B) KEGG enrichment analysis for genes
significantly associated with sex (female), genotype (5XFAD) and sex by genotype interaction (5XFAD female) relative to age-matched male B6 mice. (C) Pearson
correlation coefficients for gene expression changes in mice (log fold change of the 5XFAD mice minus age-matched B6 mice) and human disease (log fold change
for cases minus controls). AMP-AD modules are grouped into five previously identified consensus clusters describing the major functional groups of AD-related
alterations. Positive correlations are shown in blue and negative correlations in red. Color intensity and size of the circles are proportional to the correlation coefficient.
Correlations with adjusted p-value > 0.05 are considered non-significant and are left blank.
by 12 months in both the cortex (Figure 8A) and hippocampus
(Figure 8B). Interestingly, within the cortex, there were few
changes around the plaques between 5XFAD mice and controls
with the exception of an increase in P2ry12 and a decrease in
NeuN by 12 months in 5XFAD mice, likely due to previous
observations of cell loss by 12 months in this model (Oakley
et al., 2006; Jawhar et al., 2012; Eimer and Vassar, 2013;
Figure 8A). Neuron loss has been qualitatively described in the
subiculum by 9 months of age; in the neocortex, non-biased
stereological estimates suggest that 5XFAD mice lose 25–40% of
layer five pyramidal neurons between 9 and 12 months of age
(Oakley et al., 2006; Jawhar et al., 2012; Eimer and Vassar, 2013).
However, these mice do not develop a robust loss of neurons
in the hippocampus (Oakley et al., 2006; Jawhar et al., 2012;
Eimer and Vassar, 2013). However, by 12 months of age, the
level of several protein markers associated with astrocytosis and
microgliosis were elevated in the hippocampus of 5XFAD mice
(Figure 8B). These data suggest that the cortex and hippocampus
are differentially affected by amyloid deposition. These data are
in line with our biochemical data and in vivo imaging data,
as well as previously reported conventional histological staining
(Oakley et al., 2006; Jawhar et al., 2012; Eimer and Vassar,
2013).
DISCUSSION
Therapeutic interventions are desperately needed for
the treatment of AD, and the development of effective
therapeutic strategies is limited by a lack of model organisms
with disease characteristics sufficiently similar to that of
human AD (Dodart et al., 2002; Duyckaerts et al., 2008;
Citron, 2010; LaFerla and Green, 2012; Porquet et al., 2015;
Jankowsky and Zheng, 2017). This likely contributes significantly
to the challenges faced in translating animal-based findings to
human therapies and, to date, no therapies have proven effective
in clinical trials (Cavanaugh et al., 2014; Cummings et al.,
2014, 2019; Jankowsky and Zheng, 2017). The MODEL-AD
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FIGURE 5 | Mapping the progression of methoxy-X04 labeled plaque deposition across brain regions. (A) Example brain section from 4-month-old female 5XFAD
with methoxy-X04 labeled (gray) and segmentation masked plaques (red overlay). Zoom inset depicts (left to right) methoxy-X04 signal, mask (red), methoxy-X04
signal with mask overlay. (B) Plaque densities (fractional area) were quantified for all brain regions depicted as average density heat maps (red) mapped across the
entire Allen Mouse Brain Reference Atlas for 6-month-old female 5XFAD, visualized as evenly spaced selected coronal sections (top) and 3D renderings (bottom).
(C) Box plots of the plaque densities for 13 major brain regions from 2-, 3-, 4-, and 6-month-old female (top) to male (bottom) cohorts demonstrate regional plaque
density progression, plots depict median and interquartile range (IQR-25:75) whiskers depict 1.5× IQR, and diamonds for values outside the range.
FIGURE 6 | Regional increases in beta-amyloid deposition via [18F]-AV45 PET/MRI and confirmed by Autoradiography. Positron emission tomography (PET) of
radiopharmaceutical [18F]-AV45 was used to measure amyloid deposition. PET data presented as brain regions normalized to the cerebellum are quantified in
panels (A,B) at 4 and 12 months, respectively. Post-mortem autoradiography of coronal brain tissue is represented in panels (C,D).
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FIGURE 7 | Regional increases in glycolysis via [18F]-FDG PET/MRI and confirmed by Autoradiography. Positron emission tomography (PET) of radiopharmaceutical
[18F]-FDG was used to measure tissue glucose uptake. PET data presented as brain regions normalized to the cerebellum are quantified in panels (A,B) at 4 and
12 months, respectively. Post-mortem autoradiography of coronal brain tissue is represented in panels (C,D).
FIGURE 8 | NanoString GeoMX system indicates protein changes in cortex and hippocampus in 5XFAD mice compared to controls at 4 and 12 months. In the
cortex (A), several protein markers were upregulated in the 5XFAD mouse compared to controls at both time points. The greatest increases in the cortex were in
Aββ1–42 and APP, while reductions were observed in NeuN by 12 months of age. In the hippocampus (B), markers related to AD pathology (Aββ1–42, APP) as well
as inflammation were upregulated as early as 4 months of age.
consortium aims to develop more translationally relevant AD
mouse models in greater alignment with human AD and to
enhance understanding of the phenotype of AD mouse models
to facilitate enhanced translatability from mouse to human.
Here, the IU/JAX/Pitt MODEL-AD Center conducted a deep
phenotyping study of the commonly used 5XFAD mouse model,
evaluating male and female mice aged 4, 6, and 12 months
for overall frailty, cholesterol level, lipoprotein level, glucose
metabolism, behavioral test response, sleep pattern, microbiome
alteration, gene expression alteration, Aβ deposition, and
proinflammatory marker expression.
We observed that 5XFAD mice exhibit age- and sex-
based differences in total cholesterol, HDL, and LDL levels.
Increasing evidence suggests that cholesterol levels may play
an important role in AD development; specifically, low levels
of HDL and elevated levels of LDL and total cholesterol are
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associated with increased risk for neurodegenerative diseases
due to alterations in APP and Aβ accumulation, whereas
high HDL levels offer protection (Kuo et al., 1998; Yaffe
et al., 2002; Wolf et al., 2004; Eckert et al., 2010; Williamson
and Sutherland, 2011; Gamba et al., 2012; Li et al., 2012;
Posse de Chaves, 2012; Maulik et al., 2013). However, this
association remains controversial as several studies have reported
decreased risk for neurodegenerative disorders in the presence
of elevated LDL (Reitz et al., 2004, 2008; Mielke et al., 2005),
and another study indicated that cholesterol levels might be
more important at presymptomatic stages than in late-stage
disease (Pappolla et al., 2003). Indeed, to date, no benefits
to patients with AD have been observed in any clinical trial
involving cholesterol modulation with statins (Mejias-Trueba
et al., 2018). The APOE ε4 allele is a major risk factor for
LOAD development and functions as a regulator of cholesterol
in the plasma and a cholesterol transporter in the brain
(Saunders et al., 1993; de Chaves and Narayanaswami, 2008).
There is a clear need for mouse models of AD in which
cholesterol modulation in a setting such as that observed in
human AD can be evaluated to further understanding of the
true contribution of cholesterol levels to AD development
and progression.
Furthermore, we evaluated sex differences in 5XFAD mice
in comparison with WT controls at 4, 6, and 12 months of
age. As cholesterol levels are known to differ based on sex in
humans (Klingel et al., 2017), we compared male and female
mice at all time points (Figures 1A–C) and noted a significant
sex-based difference in total cholesterol in female mice in the
5XFAD and WT categories, demonstrating elevated levels in
comparison with male 5XFAD and WT mice. Female 5XFAD and
WT mice had higher LDL levels and lower HDL levels than males;
however, again, no difference between 5XFAD and WT was
observed, indicating that these alterations were not associated
with the 5XFAD genotype. In males, LDL and HDL levels were
significantly lower at 12 months of age than in 4- and 6-month-
old mice (Figures 1B,C) and HDL levels decreased significantly
between WT and 5XFAD mice at the 6- and 12-month time
points, suggesting that at the later stage of disease, HDL decrease
is associated with the 5XFAD genotype in male mice. Wirths et al.
(2006) examined plasma cholesterol in APP/PS1 mice and found
significant reductions in aged mice. These findings highlight
potential challenges in evaluating cholesterol in the context of
AD due to sex-based and age-based differences between mice that
may be related to the 5XFAD genotype.
Increased frailty is a characteristic of AD in human patients
(Song et al., 2011, 2014; Morley et al., 2013) and mouse models,
and the level to which frailty is increased is an indicator of
propensity to develop a more severe AD phenotype (Todorovic
et al., 2020). MODEL-AD has validated the frailty measure used
in the current studies, which is based on the presence and severity
of a broad spectrum of characteristics associated with aging in
mice, including changes in coat, body, and skin condition; ocular,
nasal and oral complications; balance and gait impairments, and
other age-related traits that are paralleled by the human aging
process (Sukoff Rizzo et al., 2018). While the spectrum of aging
changes tends to be subtle before 18–24 months of age in mice,
there were notable early aging traits observed at 12 months of
age in 5XFAD male and female mice that were not observed
or expected in 12-month-old age-matched controls. This may
be indicative of accumulating disease pathology in these mice.
Consistent with observations in human AD (Theou et al., 2014),
frailty scores were greater in female 5XFAD mice than in male
mice at 6 and 12 months of age, indicating that the 5XFAD
model recapitulates this sex-based divergence (Figure 2). Both
male and female 5XFAD mice exhibited robust hyperactivity
(Figure 2), consistent with previous characterizations of motor
function in this model (Jawhar et al., 2012; O’Leary et al.,
2018, 2020). As frailty and impairments in motor function are
characteristics of human AD (Buchman and Bennett, 2011;
Delrieu et al., 2016; Panza et al., 2018), these findings support the
use of the 5XFAD model for investigating interventions directed
toward improving physical condition and potentially impaired
motor function in patients with AD; in particular, where motor
function decline is observed in the preclinical stage of the disease
(Buchman and Bennett, 2011).
However, despite previous reports that 5XFAD mice have
cognitive deficits (Oakley et al., 2006; Jawhar et al., 2012),
which may be specific to the particular cognitive assay being
conducted, we did not see consistent cognitive impairment in
5XFAD mice on the C57BL/6J background at 6 or 12 months
of age relative to age- and sex-matched controls in our assays.
It is worth noting that our cognitive phenotyping was limited
in scope given the recent recommendations by the NIA to
prioritize more translational measures, which was the focus of
our resources for this project. Given that 5XFAD mice are indeed
hyperactive, we were also cognizant not to conduct cognitive
assays such as water maze, novel object recognition, or fear
conditioning that rely on motor activity and where hyperactivity
is a major confound (Sukoff Rizzo et al., 2020; Vitek et al.,
2020). Thus, we highly recommend that researchers interested
in using 5XFAD mice as a model of robust plaque deposition
also consider the confounds related to hyperactivity in any
behavioral or cognitive assay chosen, especially for studies that
will investigate the potential of novel compounds for preclinical
efficacy. For a more translational biomarker of potential synaptic
abnormalities that lead to cognitive deficits, we evaluated the
EEG, which has also been used as a functional biomarker of
mild cognitive impairment in patients with AD. Although an
abnormal EEG was previously reported in 5XFAD mice on the
hybrid background (Schneider et al., 2014; Siwek et al., 2015; Abe
et al., 2020), we did not observe significant EEG abnormalities
either as indicators of seizure activity, altered synaptic activity
related to MCI, or sleep disturbance in this study. Therefore,
we do not recommend the 5XFAD model for studies focused
on sleep or seizure disturbances in AD or for translational
studies evaluating the potential to improve cognitive deficits.
This conclusion is supported by the lack of 18F-FDG findings in
brain areas relevant for cognitive outcomes, despite alterations
in glycolysis in brain regions associated with sensory integration
and auditory function.
Furthermore, examination of the microbiome revealed that
site-specific differences are the greatest source of microbiome
variability. This could be due to multiple reasons, including
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housing conditions. Care should be taken when replicating
studies between sites to account for site differences that may
account for alterations in outcome measures.
Due to the known sex divergences in human AD and in
the 5XFAD mouse model (Theou et al., 2014; Sohn et al.,
2018; Arnold et al., 2020; O’Leary et al., 2020) and the critical
need to consider the impact of sex differences in potential
responses to treatments developed for AD (Nebel et al., 2018),
we compared the brain transcriptome of male and female 5XFAD
and WT mice, separating groups by genotype and sex with
a principal component analysis to reveal significant sex- and
genotype-disparities in gene expression (Figure 4). Previous
work by Bouter et al. (2014) examined the transcriptome of
two amyloid models (5XFAD and Tg4–42) to examine plaque-
related and non-plaque related disease factors. Interestingly,
Bouter et al. found a subset of neuroinflammation genes in
5XFAD female mice related to plaque deposition, similar to
the present study, although the present study includes both
males and females (Bouter et al., 2014). The group also
identified DEGs that were identified in both amyloid models,
suggesting disease pathways associated with behavioral deficits
and neurodegeneration (Bouter et al., 2014). Future studies
should include transcriptomics correlations with functional
outcomes to identify subsets of genes associated with specific
neurodegeneration processes. Other groups have looked at the
transcriptome of the 5XFAD model and suggest that both frontal
cortex and cerebellum in 5XFAD transgenic mice show specific
pathological processes in the early pathophysiology of AD (Kim
et al., 2012). In the present study and consistent with the
increased prevalence of and risk for AD in human females
versus males (Theou et al., 2014; Sohn et al., 2018; Arnold et al.,
2020; O’Leary et al., 2020), genes with upregulated expression in
5XFAD versus WT mice were elevated in female 5XFAD mice to
a greater extent than in male 5XFAD mice (Figure 4). Together,
previous research and the current findings indicate that the
5XFAD mouse model is appropriate for studying sex differences
in AD and for evaluating the influence of sex differences on the
efficacy of potential AD interventions in vivo.
The AMP-AD consortium has developed a systems biology
approach to characterizing changes in AD in which gene
expression from AD and control brains were compared to
build a profile of five Consensus Clusters of gene modules
associated with AD (Logsdon et al., 2019). We compared
gene expression changes in male and female 5XFAD versus
WT mice at various ages with the AMP-AD Consensus
Clusters and observed consistent gene expression changes
across all five clusters in 5XFAD mice (Figure 4). Alterations
were particularly pronounced in Consensus Cluster B, which
consists of immune system pathways. As several studies
have identified the immune system as a significant factor
in AD development and progression (Gjoneska et al., 2015;
Efthymiou and Goate, 2017), this pronounced alteration in
immune system pathways in 5XFAD mice is consistent with
the very early deposition of amyloid in this model and
the subsequent response of the immune system due to
the increased disease-related pathogenesis. Furthermore, in
Consensus Cluster E, the majority of the changes observed
were anti-correlated with human LOAD, suggesting that this
model is not satisfactory for studying pathways associated with
organelle biogenesis.
In addition to sex-based differences and gene expression
changes, 5XFAD mice were also confirmed to express several
features of AD pathology, demonstrating the model as useful
for studies relying on the use of brain imaging and Aββ
quantification strategies (Girard et al., 2013; Spencer et al.,
2013; Macdonald et al., 2014; Tang et al., 2016; Kesler et al.,
2018; Nie et al., 2019; Franke et al., 2020; Chang et al.,
2021). Specifically, PET using [18F]-FDG and PET with [18F]-
AV45 revealed significant uptake at all ages in both male and
female mice (Figures 6, 7), demonstrating that [18F]-AV45
PET/MRI is feasible for quantifying Aβ in this model but
should be confirmed with additional methods (Jankowsky and
Zheng, 2017). Our [18F]-AV45 data are consistent with previous
in vivo imaging studies in 5XFAD mice that looked at amyloid
using a different tracer (18F-Florbetaben) and observed age-
dependent increases in amyloid (Jankowsky and Zheng, 2017;
Franke et al., 2020). This study also observed alterations in brain
glucose metabolism and amyloid deposition prior to the onset
of behavioral changes (Franke et al., 2020). Although previous
studies detected cerebral hypometabolism (Franke et al., 2020),
the methods for quantification, ROI and ages of animals were
different in the present study. In addition, the animals in the
present study did not undergo behavioral studies to monitor
cognitive changes and PET imaging alterations. We utilized
TissueVision’s imaging capabilities to map the deposition of
amyloid throughout the brain over time. This is a powerful and
useful tool for determining when to intervene in the treatment
of amyloid deposition if using the 5XFAD model for preclinical
studies. Future studies would benefit from correlating in vivo
imaging studies with behavior and transcriptomics as a way
to track the behavior, neurodegeneration and transcriptomic
changes over time, similar to other work (Bouter et al., 2014;
Franke et al., 2020). As further verification for the in vivo
and ex vivo imaging studies, we confirmed that 5XFAD mice
demonstrate significantly elevated soluble Aβ40 and Aβ42 at 4, 6,
and 12 months of age in comparison with WT mice in the soluble
fraction of the hemibrain and the plasma (Supplementary
Figure 2), recapitulating findings in human AD and indicating
that 5XFAD mice are appropriate for studies focused on Aβ40 and
Aβ42 accumulation.
Neuroinflammatory changes in the brain by gene expression
matched inflammatory changes in the plasma and brain
(Supplementary Figure 2). Importantly, 5XFAD mice develop
an age-dependent increase in amyloidosis, neuron cell loss, and
neuroinflammation, as evidenced by NanoString protein analysis,
which is consistent with human AD and has been previously
reported in this model (Oakley et al., 2006; Jawhar et al., 2012;
Eimer and Vassar, 2013; Figure 8).
In summary, we conducted a deep phenotyping study
comparing 5XFAD to WT mice that revealed that 5XFAD
mice recapitulate human AD in the context of (1) frailty and
abnormal motor function, (2) sex-based alterations in condition
and gene expression, (3) immune system involvement in disease
development and (4) amyloidosis. This rigorous pipeline enables
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researchers conducting preclinical studies to make decisions on
the types of studies the 5XFAD mouse model is appropriate
for as well as which treatments to test in the 5XFAD model
based on a drug’s mechanism of action and the model’s disease
trajectory. Therefore, we recommend the use of 5XFAD mice for
AD studies focused on sex-based differences, immune regulation,
and Aβ deposition but not for translational studies evaluating the
potential of therapeutics to treat cognitive impairments. Further,
the pipeline described herein and applied to the comprehensive
phenotyping of the 5XFAD mice will be used for future studies
to comprehensively characterize new models of LOAD being
generated as part of our MODEL-AD efforts.
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Supplementary Figure 1 | The largest diversity of microbiome is site. Mice from
Indiana University, The Jackson Laboratory, and the University of Pittsburgh were
assessed between 2 and 21 months of age.
Supplementary Figure 2 | Aβ and proinflammatory cytokines are upregulated in
5XFAD brain and plasma. Significant increases in both soluble Aβ40 and Aβ42
were observed at all time points in both hemibrain (A) and plasma (B). In addition,
significantly increased proinflammatory markers were found in hemibrain (IL-β,
TNF-α) (C).
Supplementary Table 1 | Table of methoxy-X04 labeled plaque densities across
839 total brain regions in the Allen Brain Reference Atlas for all animals
(2 months – eight females, eight males; 3 months – seven females, eight males;
4 months – eight females, six males; 6 months – eight females, five males). Table
columns denote sample (sample id), brain region (structure_name), total voxels in
structure (structure_voxels), total masked plaque voxels (plaque_voxels), plaque
density (plaque_density), sample age in months (age_months), genotype
(genotype), and sex (sex).
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